Skin Cancer Clinical Trials
Skin cancer clinical trials are used to compare emerging, innovative treatments to the current standard of care. These trials offer a number of benefits, such as:
- The ability to access new, promising drugs long before they are available in other settings
- The ability to explore additional therapies when other treatments do not provide adequate benefits (as is often the case with late-stage cancers)
- The ability to contribute to new developments that will eventually benefit thousands of patients who have been diagnosed with skin cancer
At Moffitt Cancer Center, our skin cancer clinical trials have tested some of the most promising developments in treatment to date. For instance, we’ve tested several forms of immunotherapy, intralesional therapy and molecular targeted therapy. Additionally, we’re one of the only centers in the country that has the protocol to test T-cell therapies, which boost the body’s natural ability to fight cancer using its own immune system.
Florida's Largest NCI Cancer Center
Recognized as a leader in cancer excellence, Moffitt is the state's largest National Cancer Institute-designated Comprehensive Cancer Center by cancer patient volumes.
When you participate in a clinical trial at Moffitt, you can expect to have your progress monitored by a team of oncologists who specialize in skin cancer. This way, we can ensure that you’re receiving an ideal dose of the treatment and that any side effects are kept to a minimum.
Depending on the protocol of your specific trial, you may also be able to receive additional treatments here at Moffitt Cancer Center. We’ll make sure that you’re receiving the treatments that are most appropriate for your specific diagnosis, and you’ll be able to access all of your treatments in one convenient location.
For more information about the skin cancer clinical trials offered at Moffitt, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. No referral is required; our clinical trial navigators will help you determine whether you might benefit from a clinical trial, and will explain to you all of the requirements involved.
-
Clinical Trials
CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)
CLINICAL TRIAL 20641
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Binimetinib (); Encorafenib (); Nivolumab (Opdivo); Not Applicable ()
CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)
CLINICAL TRIAL 21997
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: Not Applicable (); Vismodegib (Erivedge)
CLINICAL TRIAL 22079
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOC-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Condition: Cutaneous
Intervention: IL-2 (Interleukin-2); IOV-4001 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 22279
A phase 1a/b open-label master study of pf-07799544 as a Single-agent and in combination with other targeted agents In participants with braf-mutant melanoma and other solid Tumors
Condition: Cutaneous
Intervention: PF-07284890 (); PF-07799544 (); PF-0779993 (); PF-07799933 ()
CLINICAL TRIAL 22505
Cutaneous Adverse Events (irCAEs) Associated with Immunotherapy in Patients with Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 22536
Immune Profiling of Relatlimab and Nivolumab Combination Immunotherapy for Advanced Stage Metastatic Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 22554
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Condition: Cutaneous
Intervention: Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); IL-2 (Interleukin-2); IMA203 (); Ipilimumab (); Lifileucel (); Nivolumab (Opdivo); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); paclitaxel ()
CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)
CLINICAL TRIAL 23082
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); Proleukin (Interleukin-2); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 23377
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Cemiplimab (); Fianlimab (); Nivolumab (Opdivo); REGN2810 (Cemiplimab); Relatlimab ()
CLINICAL TRIAL 23474
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); Ipilimumab (); LNS8801 (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Relatlimab (); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab)
CLINICAL TRIAL 23597
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Participants with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda); Placebo ()
CLINICAL TRIAL 23590
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-Of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Condition: Multiple
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Radiotherapy ()
CLINICAL TRIAL 23655
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
Condition: Cutaneous
Intervention: BNT326 (); BNT327 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23786
Unusual Causes of Familial and Early-Onset Cancer
Condition: Multiple
Intervention:
CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
CLINICAL TRIAL 23921
A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients
Condition: Cutaneous
Intervention: L19IL2 (); L19TNF ()
CLINICAL TRIAL 23965
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single agent and in Combination with pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BH3120 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23972
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment
Condition: Cutaneous
Intervention: L19IL2 (); L19TNF ()
CLINICAL TRIAL 24104
Evaluation of a Possible Association with Skin Microbiota and Primary Cutaneous Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24301
Identification and Evaluation of Immune and Targeted Therapies for Acral Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 24393
Establishing Melanoma PDXs for Neoantigen TCR Testing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()
Treatment